These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20936946)

  • 1. Mechanisms of monoclonal antibody-drug interactions.
    Zhou H; Mascelli MA
    Annu Rev Pharmacol Toxicol; 2011; 51():359-72. PubMed ID: 20936946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
    Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D
    J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal Antibodies: A Review.
    Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
    Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies in human organ transplantation and auto-immune diseases.
    Wijdenes J; Roy C; Morel-Fourrier B; Racadot E
    Therapie; 1992; 47(4):283-7. PubMed ID: 1494788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
    Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
    J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities.
    Sanders J; Miguel RN; Furmaniak J; Smith BR
    Methods Enzymol; 2010; 485():393-420. PubMed ID: 21050929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
    Colvin RB; Preffer FI
    Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
    Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
    Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
    Scallon B; Cai A; Radewonuk J; Naso M
    Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
    Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
    Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are monoclonal antibodies a safe treatment for cancer during pregnancy?
    Sarno MA; Mancari R; Azim HA; Colombo N; Peccatori FA
    Immunotherapy; 2013 Jul; 5(7):733-41. PubMed ID: 23829624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppression with monoclonal antibodies in multiple sclerosis.
    Hafler DA; Weiner HL
    Neurology; 1988 Jul; 38(7 Suppl 2):42-7. PubMed ID: 3260356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.
    Kang HJ; Park JS; Kim DW; Lee J; Jeong YJ; Choi SM; Lee SM; Yang SC; Yoo CG; Kim YW; Han SK; Yim JJ
    Respir Med; 2012 Mar; 106(3):443-50. PubMed ID: 22154502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD4 monoclonal antibody therapy.
    Delmonico FL; Cosimi AB
    Clin Transplant; 1996 Oct; 10(5):397-403. PubMed ID: 8930451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and experimental antibody-based therapeutics: insights, breakthroughs, setbacks and future directions.
    Murad JP; Lin OA; Espinosa EV; Khasawneh FT
    Curr Mol Med; 2013 Jan; 13(1):165-78. PubMed ID: 22834842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybridoma technology for the generation of monoclonal antibodies.
    Zhang C
    Methods Mol Biol; 2012; 901():117-35. PubMed ID: 22723097
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.